What is the recommended Matrixyl dosage?

Matrixyl dosing varies by experience level. Beginners typically start at 2mg daily, moderate users at 5mg daily, and aggressive protocols use 10mg daily.

How do you reconstitute Matrixyl?

Matrixyl comes as a pre-filled device — no reconstitution needed.

What is the half-life of Matrixyl?

The half-life of Matrixyl is Unknown (topical peptide — no systemic PK data available). This determines how frequently you need to dose for consistent blood levels.

Matrixyl

Q: What are the side effects of Matrixyl?

Generally well-tolerated as a topical cosmeceutical ingredient. Clinical studies report no increase in skin redness or barrier damage compared to vehicle moisturizer alone. Rare cases of mild, temporary irritation or slight redness at the application site may occur. Allergic contact dermatitis is theoretically possible but has not been reported at significant rates in clinical testing or post-market surveillance. No systemic side effects are expected due to minimal transdermal absorption.

Anti-AgingTopicalResearchGrade AUnknown (topical peptide — no systemic PK data available) half-life

Anti-WrinkleCollagen BoosterTopical PeptideCosmeceuticalMatrikine16 weeks on / 2 weeks off

Benefits

Stimulates production of collagen types I, III, and IV in dermal fibroblasts

Promotes fibronectin and glycosaminoglycan synthesis for improved skin structure

Reduces wrinkle depth and fine line appearance with consistent topical use

Non-invasive topical alternative to injectable collagen-stimulating treatments

Enhances extracellular matrix remodeling through matrikine signaling

Well-tolerated with an excellent safety profile confirmed by CIR Expert Panel review

Compatible with most skincare actives including retinol, vitamin C, and hyaluronic acid

Half-Life

Unknown

Route

Topical

Frequency

Daily

Vial Sizes

5mg, 10mg

BAC Water

Pre-filled

Safety Grade

Grade A

Open Matrixyl Dosage Calculator

Calculate exact syringe units for your vial and dose

About Matrixyl

Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS) is a five-amino-acid peptide with the sequence lysine-threonine-threonine-lysine-serine, conjugated to a palmitic acid chain to improve skin penetration. The KTTKS sequence was identified as the active fragment of the type I procollagen C-terminal propeptide, a naturally occurring protein released during collagen processing that signals fibroblasts to produce new extracellular matrix. This makes Matrixyl a matrikine — a peptide derived from structural proteins that acts as a biological messenger to trigger tissue repair and remodeling. When Matrixyl penetrates the skin aided by its palmitoyl lipid anchor, it interacts with TGF-beta pathways on dermal fibroblasts, upregulating gene expression for collagen types I, III, and IV, stimulating fibronectin production, promoting hyaluronic acid and glycosaminoglycan synthesis, and accelerating extracellular matrix turnover. In a 12-week, double-blind, placebo-controlled, split-face clinical study with 93 Caucasian women aged 35-55, Pal-KTTKS at 3 ppm provided statistically significant wrinkle and fine line reduction compared to placebo, as measured by both quantitative profilometry and expert grading. A separate manufacturer study at 8 ppm reported up to 68% improvement in wrinkle surface area after 4 months of twice-daily application. Skin permeation studies show that while neither KTTKS nor Pal-KTTKS fully permeates through the skin, the palmitoylated form distributes across all skin layers — with approximately 4.2 mcg/cm2 in the stratum corneum, 2.8 mcg/cm2 in the epidermis, and 0.3 mcg/cm2 in the dermis, totaling about 14.6% retention of the applied dose. Unmodified KTTKS shows no measurable skin retention, confirming the necessity of the lipid conjugation. Both forms are rapidly degraded by skin proteases, though Pal-KTTKS shows greater stability due to N-terminal blocking by the palmitic acid chain. Liposomal encapsulation is being explored to further improve delivery. The Cosmetic Ingredient Review Expert Panel has assessed pentapeptide-containing cosmetic ingredients as safe for use in cosmetic formulations. Matrixyl is not FDA-approved for any medical indication and remains a cosmeceutical research ingredient with strong in vitro data and moderate clinical evidence from manufacturer-sponsored trials.

Who Should Consider Matrixyl

Adults over 30 seeking to reduce fine lines and early wrinkles without injections
Individuals with photoaged skin looking for collagen-stimulating topical treatments
Skincare enthusiasts building multi-peptide anti-aging regimens
People who want to improve skin firmness, texture, and hydration through peptide science
Those seeking an evidence-based alternative or complement to retinoid therapy

How Matrixyl Works

Matrixyl functions as a matrikine — a bioactive peptide fragment derived from extracellular matrix proteins that acts as a cell-signaling molecule. The KTTKS sequence corresponds to residues 196-200 of the type I procollagen C-terminal propeptide, which is released during natural collagen processing. When this fragment reaches dermal fibroblasts, it triggers a feedback loop that upregulates new collagen production. The palmitoyl chain (a 16-carbon fatty acid) anchored to the N-terminus increases lipophilicity, allowing the peptide to cross the stratum corneum and reach the living epidermis and dermis. Once internalized, Matrixyl activates TGF-beta receptor-mediated signaling cascades that increase transcription of collagen I, III, and IV genes, stimulate fibronectin deposition, and promote glycosaminoglycan (including hyaluronic acid) synthesis. The net effect is accelerated extracellular matrix renewal: thicker, denser collagen networks that smooth wrinkles from within, improved dermal hydration from increased hyaluronic acid content, and enhanced skin elasticity from restored fibronectin cross-linking.

What to Expect

Week 1-2

No visible changes expected. Matrixyl begins accumulating in the upper skin layers. Some users report a subtle smoothing or hydrating sensation immediately after application due to the serum vehicle.

Weeks 2-4

Early improvements in skin texture and hydration may become noticeable. The peptide is stimulating fibroblast activity and initial collagen synthesis at the dermal level. Fine surface lines may begin to soften.

Weeks 4-8

Measurable wrinkle reduction becomes apparent. Clinical studies report significant fine line improvement by week 4. Skin firmness and elasticity begin to improve as new collagen fibers mature and integrate into the dermal matrix.

Weeks 8-16

Peak results are typically reached in this window. The Sederma clinical trial reported up to 68% wrinkle area improvement at 4 months. Deeper expression lines and nasolabial folds show continued gradual improvement as collagen remodeling progresses.

After stopping

Effects are not permanent. Wrinkle depth and skin texture gradually return toward baseline over 6-12 weeks after discontinuation as normal collagen turnover resumes without the matrikine stimulus.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	2mg	Daily
Moderate	5mg	Daily
Aggressive	10mg	Daily

Note: Topical anti-aging peptide also known as Palmitoyl Pentapeptide-4 (Pal-KTTKS). Derived from the procollagen I C-terminal propeptide (PICP), the KTTKS fragment acts as a matrikine signaling molecule that stimulates collagen synthesis. The palmitoyl chain enhances skin penetration through lipophilic stratum corneum layers. Typical serum concentrations range from 3-8 ppm (0.0003-0.0008%). Dosing tiers above reflect approximate mg of active peptide per topical application. Apply to clean, dry skin twice daily for best results.

How to Inject Matrixyl

Apply a thin layer of Matrixyl serum (3-8 ppm active peptide concentration) to clean, dry skin on target areas — typically forehead, periorbital region, nasolabial folds, and neck. Use morning and evening before moisturizer. Allow 2-3 minutes for absorption before layering other products. Matrixyl is compatible with retinoids, vitamin C, hyaluronic acid, and niacinamide, but avoid applying immediately after strong chemical exfoliants (AHAs/BHAs at peel-strength concentrations) as compromised skin barrier may alter absorption. For enhanced results, pair with GHK-Cu or SNAP-8 in a multi-peptide protocol. Do not apply to broken or actively inflamed skin.

Cycling Protocol

On Period

16 weeks

Off Period

2 weeks

Apply twice daily for 16 weeks to allow full collagen remodeling cycle. Visible improvement typically begins around week 4 and continues building through week 12-16. A 2-week break is optional — no receptor desensitization has been observed, so continuous long-term use is commonly practiced. Effects are cumulative and diminish gradually over several weeks after discontinuation.

Pharmacokinetics

Half-Life

0min

Bioavailability

Topical: <1% systemic absorption; 14.6% retained in skin layers (stratum corneum, epidermis, dermis)

Tmax

Not applicable (topical, non-systemic)

Data Confidence

low

Source: No systemic pharmacokinetic data available. Matrixyl is a topical cosmeceutical peptide with minimal transdermal absorption. Skin permeation studies (Choi et al. 2014) show 14.6% of applied Pal-KTTKS is retained across skin layers, but it does not permeate through full-thickness skin into systemic circulation.

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Generally well-tolerated as a topical cosmeceutical ingredient. Clinical studies report no increase in skin redness or barrier damage compared to vehicle moisturizer alone. Rare cases of mild, temporary irritation or slight redness at the application site may occur. Allergic contact dermatitis is theoretically possible but has not been reported at significant rates in clinical testing or post-market surveillance. No systemic side effects are expected due to minimal transdermal absorption.

Contraindications

Known allergy or hypersensitivity to palmitoyl pentapeptide-4 or any component amino acid in the KTTKS sequence
Active skin infections, open wounds, or severe dermatitis at intended application sites
Pregnancy or breastfeeding (no safety data available for this population)
Children under 18 (insufficient safety data)
History of contact dermatitis to cosmeceutical peptide products

Drug Interactions

Topical retinoids (tretinoin, adapalene) — may increase transient skin sensitivity when layered simultaneously; apply at separate times of day for best tolerance
High-concentration chemical peels (glycolic acid >20%, TCA peels) — compromised skin barrier after peeling may alter peptide absorption; wait 48-72 hours post-peel before resuming
Other collagen-stimulating peptides (GHK-Cu, AHK-Cu) — additive collagen-boosting effects are expected and generally considered beneficial in combination protocols
Topical corticosteroids — prolonged steroid use thins the dermis and may reduce the substrate available for Matrixyl-stimulated collagen remodeling